


Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Original) A compound of formula (I):



wherein:

Y is -C(O)-, -CH<sub>2</sub>-, -CH<sub>2</sub>C(O)- or -SO<sub>2</sub>-;

R<sub>1</sub> and R<sub>2</sub> are each independently C<sub>1-8</sub>-alkyl, CF<sub>2</sub>H, CF<sub>3</sub>, CH<sub>2</sub>CHF<sub>2</sub>, cycloalkyl, or (C<sub>1-8</sub>-alkyl)cycloalkyl;

Z<sub>1</sub> is H, C<sub>1-6</sub>-alkyl, NH<sub>2</sub>, NR<sub>3</sub>R<sub>4</sub> or OR<sub>5</sub>;

Z<sub>2</sub> is H or C(O)R<sub>5</sub>;

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are each independently H, halogen, NO<sub>2</sub>, OR<sub>3</sub>, CF<sub>3</sub>, C<sub>1-6</sub>-alkyl, (C<sub>0-4</sub>-alkyl)-(C<sub>3-6</sub>-cycloalkyl), (C<sub>0-4</sub>-alkyl)-N-(R<sub>8</sub>R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)-(R<sub>8</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)CH(R<sub>8</sub>)(R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)N(R<sub>8</sub>R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)O(R<sub>8</sub>), (C<sub>0-4</sub>-alkyl)-O-R<sub>8</sub>, (C<sub>0-4</sub>-alkyl)-imidazolyl, (C<sub>0-4</sub>-alkyl)-pyrrolyl, (C<sub>0-4</sub>-alkyl)-oxadiazolyl, (C<sub>0-4</sub>-alkyl)-triazolyl or (C<sub>0-4</sub>-alkyl)-heterocycle;

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each independently H, C<sub>1-6</sub>-alkyl, O-C<sub>1-6</sub>-alkyl, phenyl, benzyl, or aryl;

R<sub>6</sub> and R<sub>7</sub> are independently H or C<sub>1-6</sub>-alkyl;

R<sub>8</sub> and R<sub>9</sub> are each independently H, C<sub>1-9</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, (C<sub>1-6</sub>-alkyl)-(C<sub>3-6</sub>-cycloalkyl), (C<sub>0-6</sub>-alkyl)-N(R<sub>4</sub>R<sub>5</sub>), (C<sub>1-6</sub>-alkyl)-OR<sub>5</sub>, phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrrolidinyl, morpholino, or C<sub>3-7</sub>-heterocycloalkyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) The compound of claim 1 wherein Y is -CH<sub>2</sub>- or -C(O)-.

3. (Original) The compound of claim 1 wherein Z<sub>1</sub> is H.

4. (Original) The compound of claim 3 wherein R<sub>6</sub> is C<sub>1-6</sub>-alkyl and R<sub>7</sub> is H.
5. (Original) The compound of claim 1 wherein Z<sub>2</sub> is H, -C(O)CH<sub>3</sub> or -C(O)CH<sub>2</sub>CH<sub>3</sub>.
6. (Original) The compound of claim 5 wherein X<sub>4</sub> is NHC(O)R<sub>8</sub>.
7. (Original) The compound of claim 5 wherein R<sub>1</sub> is CH<sub>3</sub> or CF<sub>2</sub>H and R<sub>2</sub> is C<sub>1-8</sub>-alkyl.
8. (Original) The compound of claim 5 wherein Z<sub>2</sub> is H.
9. (Original) The compound of claim 1 wherein R<sub>1</sub> is CH<sub>3</sub> or CF<sub>2</sub>H.
10. (Original) The compound of claim 1 wherein R<sub>2</sub> is CH<sub>2</sub>CH<sub>3</sub>, CH<sub>3</sub>, CF<sub>2</sub>H, CH<sub>2</sub>-cyclopropyl, or cyclopentyl.
11. (Original) The compound of claim 1 wherein R<sub>6</sub> and R<sub>7</sub> are both H or one of R<sub>6</sub> and R<sub>7</sub> is H and the other is CH<sub>3</sub>.
12. (Original) The compound of claim 1 wherein X<sub>4</sub> is -NHC(O)R<sub>8</sub> and X<sub>1</sub> is H or halogen.
13. (Original) The compound of claim 1 wherein one of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> is NHCOCH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, NHCON(CH<sub>3</sub>)<sub>2</sub>, NHCONH<sub>2</sub>, NHCOCH<sub>3</sub>, NHCOCH(R<sub>8</sub>)N(R<sub>7</sub>R<sub>8</sub>) or OCH<sub>3</sub>, and the rest of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are H.
14. (Original) The compound of claim 1, wherein the configuration of stereocenter **a** is (S).
15. (Original) The compound of claim 1, wherein the configuration of stereocenter **a** is (R).
16. (Original) The compound of claim 1, wherein R<sub>6</sub> and R<sub>7</sub> are not same, and the configuration of stereocenter **b** is (S).

17. (Original) The compound of claim 1, wherein R<sub>6</sub> and R<sub>7</sub> are not same, and the configuration of stereocenter **b** is (R).

18. (Original) A diastereomerically pure SS isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

19. (Original) A diastereomerically pure RS isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

20. (Original) A diastereomerically pure SR isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

21. (Original) A diastereomerically pure RR isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

22. (Original) A compound, where the compound is:

(3R)-(tert-Butoxy)-N-{3-[7-(cyclopropylcarbonylamino)-1-oxoisooindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl} carbonylamino (tert-butoxy)formate;  
N-[3-(7-Amino-1-oxoisooindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propyl](tert-butoxy)carbonylamino (tert-butoxy)formate;  
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;  
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide;  
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;  
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide;  
(1R)-N-{2-[3-(N-Acetoxy-N-formyl-amino)-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;


(1R)-N-{2-[3-(N-Aminocarbonyl-N-hydroxy-amino)-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(N-{3-[7-(Cyclopropylcarbonylamino)-1-oxoisooindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl}acetylamino) acetate; or

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(formyl-hydroxy-amino)-butyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.

23. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula (I):



wherein:

Y is -C(O)-, -CH<sub>2</sub>- , -CH<sub>2</sub>C(O)-or -SO<sub>2</sub>;

R<sub>1</sub> and R<sub>2</sub> are each independently C<sub>1-8</sub>-alkyl, CF<sub>2</sub>H, CF<sub>3</sub>, CH<sub>2</sub>CHF<sub>2</sub>, cycloalkyl, or (C<sub>1-8</sub>-alkyl)cycloalkyl;

Z<sub>1</sub> is H, C<sub>1-6</sub>-alkyl, NH<sub>2</sub>, NR<sub>3</sub>R<sub>4</sub> or OR<sub>5</sub>;

Z<sub>2</sub> is H or C(O)R<sub>5</sub>;

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are each independently H, halogen, NO<sub>2</sub>, OR<sub>3</sub>, CF<sub>3</sub>, C<sub>1-6</sub>-alkyl, (C<sub>0-4</sub>-alkyl)-(C<sub>3-6</sub>-cycloalkyl), (C<sub>0-4</sub>-alkyl)-N-(R<sub>8</sub>R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)-(R<sub>8</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)CH(R<sub>8</sub>)(R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)N(R<sub>8</sub>R<sub>9</sub>), (C<sub>0-4</sub>-alkyl)-NHC(O)O(R<sub>8</sub>), (C<sub>0-4</sub>-alkyl)-O-R<sub>8</sub>, (C<sub>0-4</sub>-alkyl)-imidazolyl, (C<sub>0-4</sub>-alkyl)-pyrrolyl, (C<sub>0-4</sub>-alkyl)-oxadiazolyl, (C<sub>0-4</sub>-alkyl)-triazolyl or (C<sub>0-4</sub>-alkyl)-heterocycle;

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each independently H, C<sub>1-6</sub>-alkyl, O-C<sub>1-6</sub>-alkyl, phenyl, benzyl, or aryl;

R<sub>6</sub> and R<sub>7</sub> are independently H or C<sub>1-6</sub>-alkyl;

R<sub>8</sub> and R<sub>9</sub> are each independently H, C<sub>1-9</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, (C<sub>1-6</sub>-alkyl)-(C<sub>3-6</sub>-cycloalkyl), (C<sub>0-6</sub>-alkyl)-N(R<sub>4</sub>R<sub>5</sub>), (C<sub>1-6</sub>-alkyl)-OR<sub>5</sub>, phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrrolidinyl, morpholino, or C<sub>3-7</sub>-heterocycloalkyl;

or a pharmaceutically acceptable salt or solvate thereof.

24. (Original) The pharmaceutical composition of claim 23 further comprising an additional therapeutic agent.

25. (Original) The pharmaceutical composition of claim 24 wherein the additional therapeutic agent is an anti-cancer agent or an anti-inflammatory agent.

26. (Original) The pharmaceutical composition of claim 25 wherein the anti-cancer agent is paclitaxel, cisplatin, tamoxifen, docetaxel, pirubicin, doxorubicin, irinotecan, leuprolide, bicalutamide, a goserlin implant, gemcitabine, sargramostim or a steroid.

Claims 27-57. Canceled without prejudice.